Korsana Biosciences, Inc. (KRSA)
30.14
-0.08
(-0.26%)
USD |
NASDAQ |
Oct 30, 16:00
30.13
-0.01
(-0.03%)
After-Hours: 20:00
Korsana Biosciences Cash from Investing (Quarterly) : 0.00 for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | -0.066M |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 10.40M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.00 |
| September 30, 2021 | -0.007M |
| June 30, 2021 | 0.002M |
| March 31, 2021 | 1.462M |
| December 31, 2020 | 1.436M |
| September 30, 2020 | 0.003M |
| June 30, 2020 | -0.065M |
| March 31, 2020 | -1.356M |
| December 31, 2019 | -0.10M |
| September 30, 2019 | -0.554M |
| June 30, 2019 | -4.247M |
| March 31, 2019 | -1.814M |
| December 31, 2018 | -1.816M |
| September 30, 2018 | -1.16M |
| June 30, 2018 | -0.30M |
| March 31, 2018 | -0.162M |
| December 31, 2017 | -0.436M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Q32 Bio, Inc. | 0.00 |
| IRulya Therapeutics, Inc. | 8.001M |
| Climb Bio, Inc. | -57.26M |
| PepGen Inc. | -3.516M |
| Bridgebio Oncology Therapeutics, Inc. | 45.73M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.432M |
| Free Cash Flow | -4.517M |
| Free Cash Flow Per Share (Quarterly) | -2.358 |
| Free Cash Flow to Equity (Quarterly) | -1.432M |
| Free Cash Flow to Firm (Quarterly) | -1.432M |
| Free Cash Flow Yield | -27.07% |